Anti-CEACAM5 Antibody-drug Conjugate IBI3020

**Semantic type:** Pharmacologic Substance

**Definition:** An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5; CEA) conjugated to both a DNA topoisomerase I inhibitor (TOP1i) and the auristatin derivative and microtubule disrupting agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration of anti-CEACAM5 ADC IBI3020, the antibody moiety targets and binds to CEACAM5 expressed on tumor cells. Upon binding and internalization, the TOP1i and MMAE are released. The TOP1i inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and apoptosis in CEACAM5-expressing tumor cells. MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M checkpoint arrest and apoptosis in CEACAM5-expressing tumor cells. CEACAM5, a member of the CEA family of proteins that plays a key role in cell migration, cell invasion, and cell adhesion, is overexpressed by a variety of cancer cell types.

**Synonyms:** - ADC IBI3020 - Anti-CEA ADC IBI3020 - Anti-CEA Antibody-drug Conjugate IBI3020 - Anti-CEACAM5 ADC IBI3020 - Anti-CEACAM5 Dual Payload ADC IBI3020 - Anti-CEACAM5/TOP1i/MMAE Antibody-drug Conjugate IBI3020 - CEACAM5 DP ADC IBI3020 - IBI 3020 - IBI-3020 - IBI3020